Skip to main content
Bioera logo

Bioera — Investor Relations & Filings

Ticker · BIE ISIN · IT0005516130 LEI · 815600CE609AFE44D992 XMIL Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2023-07-10 Regulatory Filings
Country IT Italy
Listing XMIL BIE

About Bioera

https://bioera.it/en/

Bioera S.p.A. is a company specializing in the production and distribution of natural and organic products. Its core business involves the development and marketing of a diverse portfolio that includes organic food, traditional food products, natural cosmetics, herbal remedies, and food supplements. The company focuses on providing consumers with products derived from natural sources, catering to the health and wellness market.

Recent filings

Filing Released Lang Actions
BIOERA SPA - Precisazione al Comunicato Stampa del 7 luglio 2023
Regulatory Filings Classification · 1% confidence The document is a formal communication titled "Precisazione al Comunicato Stampa del 07.07.2023" (Clarification to the Press Release of 07/07/2023). It discusses updates related to a convertible bond, the approval of the 2022 consolidated financial statements, a related party transaction (loan), and a proposal to acquire assets in a simplified arrangement procedure. The document itself is short (under 5,000 characters) and explicitly states "Vedi allegato" (See attachment) and then proceeds to clarify previous announcements. This structure—a brief announcement clarifying or referencing other, larger documents (like the Supplemento Informativo or previous press releases)—strongly suggests it is an announcement about regulatory information rather than the full report itself. Since it is a formal, specific regulatory update that doesn't fit the definitions for ER, IR, 10-K, or specific corporate actions like DIV or SHA, the most appropriate general category for a specific regulatory clarification that doesn't fit elsewhere is Regulatory Filings (RNS). However, given the content heavily revolves around capital structure changes (convertible bond, capital increase) and related party transactions, it touches upon financing/capital activities. Since it is a clarification of a previous announcement regarding a capital increase/convertible bond, it is closely related to financing. If it were the primary announcement of the financing, CAP would fit. As a clarification of regulatory filings, RNS is a strong candidate. Given the context of Italian regulatory filings (Informazione Regolamentata), RNS serves as the best general regulatory announcement fallback when a more specific code (like CAP for the underlying financing event) is not the primary focus of *this* specific document, which is merely a clarification. I will classify it as RNS as it is a general regulatory update/clarification.
2023-07-10 Italian
BIOERA SPA- Pubblicazione supplemento informativo
Report Publication Announcement Classification · 1% confidence The document is an official communication from BIOERA S.p.A. titled 'COMUNICATO STAMPA' (Press Release). The key subject ('Oggetto') is 'BIOERA SPA- Pubblicazione supplemento informativo' (Publication of information supplement). The text explicitly states that CONSOB authorized the 'Supplemento Informativo' (Information Supplement) related to the admission of new shares resulting from a capital increase tied to a convertible bond. Crucially, the document states, 'Pubblicato il Supplemento Informativo' (The Information Supplement has been published) and directs the reader to see the attachment ('Vedi allegato') and notes that the Supplement is available on the company website. This structure—announcing the publication of a regulatory document (the Supplement) rather than being the full, detailed Supplement itself—fits the definition of a Report Publication Announcement (RPA). The document length (5374 chars) is consistent with a short announcement rather than a full prospectus or financial report.
2023-07-07 Italian
BIOERA SPA - Secondo Supplemento 07/07/2023 (DEPROEM)
Capital/Financing Update Classification · 1% confidence The document is titled "SUPPLEMENTO AL PROSPETTO INFORMATIVO" (Supplement to the Prospectus) and explicitly states it is an update to a previously filed Prospectus Informativo (Prospectus) concerning a capital increase and admission to trading. It references regulatory frameworks (Regolamento (UE) 2017/1129) and regulatory bodies (Consob). A supplement to a prospectus, especially one related to capital raising (Aumento di capitale), is a specific type of disclosure document. While it is an update, it is not the initial offering document (like a full Prospectus or 10-K) nor is it a general announcement of a report (RPA). It is a formal regulatory filing providing material updates to the base prospectus. Given the options, this document relates directly to capital structure changes and financing activities, making 'Capital/Financing Update' (CAP) a strong candidate, as it supplements the terms of a capital increase. However, the core nature of the document is a formal regulatory filing that supplements a Prospectus, which is often categorized under broader regulatory disclosure rules. Since the document is a formal supplement to a Prospectus related to a capital increase, it fits best under 'Capital/Financing Update' (CAP) as it directly modifies the terms of the offering, or potentially 'Regulatory Filings' (RNS) if CAP is reserved strictly for initial announcements. Given the detailed nature of the update (incorporating year-end financials and related party transactions into the existing offering document), CAP is the most specific fit for the *content* being updated, even though it is presented as a supplement. If the document were purely announcing the publication of this supplement, RPA would apply, but this text *is* the supplement itself. I will classify it as CAP due to the subject matter (capital increase update).
2023-07-07 Italian
BIOERA SPA - Rendiconto sintetico votazioni assemblea ordinaria degli azionisti del 5 luglio 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'rendiconto sintetico votazioni assemblea ordinaria degli azionisti del 5 luglio 2023' (summary report of voting at the ordinary shareholders' meeting of July 5, 2023). It details the voting results for several resolutions, including the approval of the 2022 financial statements, capital reduction due to losses, and remuneration policy votes. This content directly relates to the outcomes of a shareholder meeting. The most specific category for official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it contains financial information (like the approval of the balance sheet), its primary function here is reporting the voting outcome, not being the full Annual Report (10-K) or a standalone Audit Report (AR). It is not an AGM presentation (AGM-R) but the results thereof.
2023-07-06 Italian
BIOERA SPA - Assemblea ordinaria degli azionisti del 5 luglio 2023 in seconda convocazione
AGM Information Classification · 1% confidence The document is a press release (COMUNICATO STAMPA) detailing the resolutions passed during the Ordinary Shareholders' Meeting (Assemblea ordinaria degli azionisti) held on July 5, 2023. Key resolutions include the approval of the 2022 financial statements, capital reduction due to losses, and the appointment of the Board of Statutory Auditors (collegio sindacale) for the 2023-2025 term. The subject line explicitly mentions the 'Assemblea ordinaria degli azionisti'. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2023-07-05 Italian
BIOERA SPA - Informativa mensile POC Giugno 2023
Capital/Financing Update Classification · 1% confidence The document is a monthly disclosure ('Informativa mensile') regarding a convertible bond loan (POC) issued by Bioera S.p.A. It provides specific details on capital structure changes, including bond conversions and share issuances, in compliance with Consob regulatory requirements (art. 114, comma 5, d.lgs. 58/1998). While it contains financial data, it is a periodic regulatory disclosure regarding financing instruments rather than a full financial report or an earnings release. Given the nature of the disclosure regarding capital structure and financing instruments, it fits best under 'Capital/Financing Update'. H1 2023
2023-07-03 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.